GDTC
CytoMed Therapeutics Limited Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$11.71M
P/E Ratio
—
EPS
$-0.27
Beta
-0.21
52W High
$3.68
52W Low
$0.73
50-Day MA
$1.03
200-Day MA
$1.57
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company is headquartered in Singapore.
Fundamentals
| Revenue (TTM) | 860,850 |
| Gross Profit (TTM) | 771,090 |
| EBITDA | $-3.85M |
| Operating Margin | -535.00% |
| Return on Equity | -50.30% |
| Return on Assets | -29.30% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $0.43 |
| Price-to-Book | 2.28 |
| Price-to-Sales (TTM) | 13.61 |
| EV/Revenue | 41.11 |
| EV/EBITDA | -4.45 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 46.90% |
| Shares Outstanding | $11.83M |
| Float | $3.97M |
| % Insiders | 67.83% |
| % Institutions | 0.49% |
Historical Volatility
HV 10-Day
78.48%
HV 20-Day
67.34%
HV 30-Day
61.02%
HV 60-Day
75.42%
HV Rank
28.6%
Volatility is currently expanding
Data last updated: 4/30/2026